You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
2022-03-31
Mar 31, 2022
S
Completed
  • Lymphoma, Large B-Cell, Diffuse
  • FDG PET radiomic feature evaluation
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
2021-09-27
Sep 27, 2021
H
Recruiting
  • Lymphoma, Large B-Cell, Diffuse
    • Copenhagen, Denmark
      Department of Hematology, Rigshospitalet
    2022-01-12
    Jan 12, 2022
    W
    Completed
    • Lymphoma, Large B-Cell, Diffuse
    • Saint Louis, Missouri
    • +1 more
    2022-02-16
    Feb 16, 2022
    R
    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • +2 more
    • PD-1 Inhibitor Tislelizumab maintenance therapy
    • Shanghai, Shanghai, China
      Ruijin Hospital
    2021-11-14
    Nov 14, 2021
    U
    P
    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • Digital Health Coaching
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    2022-01-19
    Jan 19, 2022
    U
    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    2022-02-02
    Feb 2, 2022
    N
    Completed
    • Lymphoma, Large-Cell, Anaplasitc
    • +4 more
    • Anti-CD30-CAR T cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-01-27
    Jan 27, 2022
    C
    Not yet recruiting
    • Lymphoma, Non-Hodgkin
    • +3 more
      • (no location specified)
      2021-07-20
      Jul 20, 2021
      U
      Recruiting
      • Pneumococcal Infections
      • Lymphoma, Large B-Cell, Diffuse
      • Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
      • Tours, France
        GYAN
      2021-05-17
      May 17, 2021
      R
      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
        • (no location specified)
        2021-12-27
        Dec 27, 2021
        N
        Active, not recruiting
        • Lymphoma, AIDS-related
        • Lymphoma, Large B-Cell, Diffuse
        • Rituximab
        • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2022-03-11
        Mar 11, 2022
        J
        Available
        • Lymphoma, Large B-Cell, Diffuse
        • Nonconforming Lisocabtagene Maraleucel
        • (no location specified)
        2022-01-11
        Jan 11, 2022
        F
        Recruiting
        • Diffuse Large B Cell Lymphoma
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        2022-03-13
        Mar 13, 2022
        T
        Active, not recruiting
        • Lymphoma, B-Cell
        • San Antonio, Texas
          Mays Cancer Center, UT Health San Antonio
        2022-03-09
        Mar 9, 2022
        A
        No longer available
        • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
        • Loncastuximab Tesirine
        • (no location specified)
        2021-05-10
        May 10, 2021
        C
        Not yet recruiting
        • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
        • With and Without MyD88 and/or CD79B Mutations
        • (no location specified)
        2022-04-01
        Apr 1, 2022
        B
        Not yet recruiting
        • Relapsed Diffuse Large B-cell Lymphoma
        • loncastuximab tesirine
        • Detroit, Michigan
          Barbara Ann Karmanos Cancer Institute
        2022-01-24
        Jan 24, 2022
        U
        Completed
        • Diffuse, Large B-Cell, Lymphoma
        • Los Angeles, California
          USC Norris Comprehensive Cancer Center
        2021-11-15
        Nov 15, 2021
        C
        Recruiting
        • Diffuse Large B Cell Lymphoma
        • 18F-FDG PET SCAN
        • MRI DIFFUSION
        • Nice, France
          Centre antoine-LACASSAGNE
        2021-11-09
        Nov 9, 2021
        R
        Not yet recruiting
        • Lymphoma, Large B-Cell, Diffuse
        • +2 more
        • PD-1 Inhibitor Tislelizumab maintenance therapy
        • Shanghai, Shanghai, China
          Ruijin Hospital
        2021-03-15
        Mar 15, 2021
        D
        Recruiting
        • Diffuse Large B Cell Lymphoma
        • +2 more
        • Boston, Massachusetts
          Dana-Farber Cancer Institute
        2021-09-08
        Sep 8, 2021
        M
        Active, not recruiting
        • Large B-Cell Diffuse Lymphoma
        • Charleston, South Carolina
          Medical University of South Carolina
        2022-03-31
        Mar 31, 2022
        N
        Completed
        • Relapsed Non Hodgkin Lymphoma
        • Refractory Lymphoma
          • Taipei, Taiwan
            National Taiwan University Hospital
          2021-08-08
          Aug 8, 2021